Liquid Biopsy Profiling with Multiple Tests in Patients with Metastatic Breast Cancer [0.03%]
乳腺癌患者多种检测的液体活检分析
Nikki Higa,Lisa Welter,Liya Xu et al.
Nikki Higa et al.
The chief goal of the Blood Profiling Atlas in Cancer (BloodPAC) consortium is to promote collaborative efforts that support the development and implementation of liquid biopsy tests....Here, we report the results of a pilot study conducted by three BloodPAC members that aimed to demonstrate a multisite liquid biopsy testing framework using longitudinal blood specimens from 38 patients with metastatic breast cancer....Overall, the framework described in this study may serve as a resource for future trials aiming to identify multimodal liquid biopsy biomarkers to guide clinical care.
Detection of KRAS, NRAS and BRAF Mutations in Liquid Biopsy from Patients with Colorectal Cancer [0.03%]
结直肠癌患者液体活检中KRAS、NRAS和BRAF基因突变的检测分析
Katerina Ondraskova,Matous Cwik,Ondrej Horky et al.
Katerina Ondraskova et al.
The ctDNA obtained through liquid biopsy was analyzed using ddPCR, and the findings were compared with sequencing data from tumor DNA archived in formalin-fixed paraffin-embedded (FFPE) blocks.
Biomarker Testing Practices for Non-small Cell Lung Cancer: Survey Insights from South Korean Pathology Laboratories [0.03%]
韩国病理实验室非小细胞肺癌生物标志物检测实践调查见解
Sehui Kim,Dajeong Kim,Lucia Kim et al.
Sehui Kim et al.
Tissue was the primary specimen type, and cytology and liquid biopsy specimens were accepted by 90.0% and 46.7% of institutions, respectively.
Liquid biopsy biomarkers for accurate detection of malignant pulmonary nodules: a meta-analytic approach [0.03%]
液体活检生物标志物在恶性肺结节准确检测中的价值： meta-分析方法
Alberto Caballero-Vazquez,Marta Garcia-Cerezo,Laura R Fernandez-Castro et al.
Alberto Caballero-Vazquez et al.
This study aims to evaluate the diagnostic capacity of multiple liquid biopsy biomarkers for early and accurate differentiation between benign and Malignant pulmonary nodules....Accordingly, we conducted a comprehensive study involving a meta-analysis, selecting 16 eligible studies that utilised liquid biopsy to assess various circulating biomarkers in the diagnostic yield. The most significant results were linked to circulating free DNA (cfDNA).
Non-invasive liquid biopsy based on metabolomic profiling improves diagnosis and early warning of severe acute pancreatitis [0.03%]
基于代谢组学谱型的无创液体活检提高重症急性胰腺炎诊断及预警效能
Dawei Deng,Qihang Yuan,Chen Pan et al.
Dawei Deng et al.
To identify novel diagnostic biomarkers for acute pancreatitis (AP) and facilitate the early prediction of severe AP (SAP), this investigation characterized the serum metabolomic profiles of patients across distinct disease phases and integ...
CADEM: Species-level detection of mycobacterial cfDNA via CRISPR for pulmonary disease diagnosis [0.03%]
基于CRISPR的肺病原体分枝杆菌cfDNA种水平检测方法(CADEM)
Seungil Park,Bonhan Koo,Myoung Gyu Kim et al.
Seungil Park et al.
To address these limitations, liquid biopsy using bacterial-derived circulating cell-free DNA (cfDNA) offers a minimally invasive alternative, and CRISPR/Cas12a technology provides the sensitivity required to detect its low levels....By combining microfluidic cfDNA enrichment with CRISPR-based detection, CADEM enables efficient analysis from liquid biopsy samples for pulmonary disease diagnosis.
Thermosensitive hydrogel-enhanced RPA-CRISPR/Cas12a biosensor for ultrasensitive detection of methylated loci in breast cancer ctDNA [0.03%]
热响应水凝胶增强的RPA-CRISPR / Cas12a生物传感器可超灵敏地检测乳腺癌ctDNA中的甲基化位点
Jianxun Hou,Yingjie Wang,Weiguang Yuan et al.
Jianxun Hou et al.
The release of methylated circulating tumor DNA (ctDNA) by tumor cells provides a foundation for breast cancer liquid biopsy using methylated ctDNA. However, detection of low-abundance methylated loci in ctDNA remains a significant challenge to date.
Rapid liquid biopsy assessment through gene profiling from the kidney biopsy transport medium: a technical validation and a proof-of-concept pilot study [0.03%]
通过肾脏活检运送介质进行快速液体活检评估的技术验证和概念验证试点研究：基因谱分析
Ziyang Li,Marij J P Welters,Hailiang Mei et al.
Ziyang Li et al.
Rapid diagnosis is pivotal in kidney disease for timely and precision therapy. Conventional microscopic and molecular assessments from biopsy tissues rely on extra sample processing, making same-day diagnosis impractical. Therefore, we intr...
Recent advances in the management of pancreatic neuroendocrine tumors: From diagnosis, treatment to biology [0.03%]
胰腺神经内分泌肿瘤的诊治近进及生物学特性研究进展
Senjie Dai,Wuhu Zhang,Heli Gao et al.
Senjie Dai et al.
The development of liquid biopsy technologies (such as CTCs and NETest) has opened new avenues for the early diagnosis of PNETs. Considerable heterogeneity among PNETs represents a major challenge to their effective clinical management.
Organ preservation in rectal cancer: an endoscopist's perspective on current evidence and future directions [0.03%]
直肠癌的器官保存：内镜医师视角下的当前证据与未来方向
Takashi Kanesaka,Kenichiro Imai,Hiroaki Ikematsu et al.
Takashi Kanesaka et al.
Refined histopathological risk criteria, predictive nomograms, artificial intelligence-based models, and emerging liquid biopsy biomarkers, such as circulating tumour DNA, are being explored to better estimate the risk of lymph node metastasis after endoscopic resection.
耗时 0.07636 秒，为您在
49315348
条记录里面共找到 6666 篇文章 [XML]